A DNA-interacting payload designed to eliminate cross-linking improves the therapeutic index of antibody–drug conjugates (ADCs)

Molecular Cancer Therapeutics

Volumn 17, Issue 3, 2018, Pages 650-660

  Miller, Michael L ^a   Shizuka, Manami ^a   Wilhelm, Alan ^a   Salomon, Paulin ^a   Reid, Emily E ^a   Lanieri, Leanne ^a   Sikka, Surina ^a   Maloney, Erin K ^a   Harvey, Lauren ^a   Qiu, Qifeng ^a   Archer, Katie E ^a   Bai, Chen ^a   Vitharana, Dilrukshi ^a   Harris, Luke ^a   Singh, Rajeeva ^a   Ponte, Jose F ^a   Yoder, Nicholas C ^a   Kovtun, Yelena ^a   Lai, Katharine C ^a   Ab, Olga ^a   Pinkas, Jan ^a   Keating, Thomas A ^a   Chari, Ravi V J ^a   more..

^a IMMUNOGEN INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY DRUG CONJUGATE; CYTOTOXIC AGENT; INDOLINOBENZODIAZEPINE EPITHELIAL CELL ADHESION MOLECULE ANTIBODY CONJUGATE; INDOLINOBENZODIAZEPINE FOLATE RECEPTOR ALPHA ANTIBODY CONJUGATE; INDOLINOBENZODIAZEPINE SOYBEAN TRYPSIN INHIBITOR CONJUGATE; UNCLASSIFIED DRUG; ALKYLATING AGENT; ANTIBODY CONJUGATE; CROSS LINKING REAGENT; DNA; INTERCALATING AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN EXPRESSION; ANTINEOPLASTIC ACTIVITY; ARTICLE; CONTROLLED STUDY; CYTOTOXICITY; DNA ALKYLATION; DNA CROSS LINKING; DOSE; DRUG DESIGN; DRUG DNA BINDING; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; HUMAN; HUMAN CELL; IC50; IN VITRO STUDY; IN VIVO STUDY; LUNG ADENOCARCINOMA; MOUSE; NON SMALL CELL LUNG CANCER; NONHUMAN; OVARY ADENOCARCINOMA; PRIORITY JOURNAL; SINGLE DRUG DOSE; STRUCTURE ACTIVITY RELATION; THERAPEUTIC INDEX; ANIMAL; CELL SURVIVAL; CHEMISTRY; DRUG EFFECT; DRUG SCREENING; DRUG THERAPEUTIC INDEX; GENETICS; METABOLISM; NEOPLASM; PATHOLOGY; TUMOR CELL LINE; TUMOR VOLUME;

ANIMALS; ANTINEOPLASTIC AGENTS, ALKYLATING; CELL LINE, TUMOR; CELL SURVIVAL; CROSS-LINKING REAGENTS; DNA; DRUG DESIGN; HUMANS; IMMUNOCONJUGATES; INTERCALATING AGENTS; MICE; NEOPLASMS; THERAPEUTIC INDEX, DRUG; TUMOR BURDEN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 85047735699     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-17-0940     Document Type: Article

References (37)

1. Chari RV, Miller ML, Widdison WC. Antibody–drug conjugates: an emerging concept in cancer therapy. Angewandte Chemie 2014;53:3796–827.
2. Sievers EL, Senter PD. Antibody–drug conjugates in cancer therapy. Annu Rev Med 2013;64:15–29.
3. Chudasama V, Maruani A, Caddick S. Recent advances in the construction of antibody–drug conjugates. Nat Chem 2016;8:114–9.
4. Casi G, Neri D. Antibody–drug conjugates and small molecule-drug conjugates: opportunities and challenges for the development of selective anticancer cytotoxic agents. J Med Chem 2015;58:8751–61.
5. Amiri-Kordestani L, Blumenthal GM, Xu QC, Zhang L, Tang SW, Ha L, et al. FDA approval: ado-trastuzumab emtansine for the treatment of patients with HER2-positive metastatic breast cancer. Clin Cancer Res 2014;20: 4436–41.
6. Katz J, Janik JE, Younes A. Brentuximab vedotin (SGN-35). Clin Cancer Res 2011;17:6428–36.
7. Kantarjian HM, DeAngelo DJ, Stelljes M, Martinelli G, Liedtke M, Stock W, et al. Inotuzumab ozogamicin versus standard therapy for acute lympho-blastic leukemia. N Engl J Med 2016;375:740–53.
8. Chari RV. Expanding the reach of antibody–drug conjugates. ACS Med Chem Lett 2016;7:974–6.
9. Beck A, Goetsch L, Dumontet C, Corvaia N. Strategies and challenges for the next generation of antibody–drug conjugates. Nat Rev Drug Discov 2017; 16:315–37.
10. Mantaj J, Jackson PJ, Rahman KM, Thurston DE. From anthramycin to pyrrolobenzodiazepine (PBD)-containing antibody–drug conjugates (ADCs). Angew Chem Int Ed Engl 2017;56:462–88.
11. Kung Sutherland MS, Walter RB, Jeffrey SC, Burke PJ, Yu C, Kostner H, et al. SGN-CD33A: a novel CD33-targeting antibody–drug conjugate utilizing a pyrrolobenzodiazepine dimer is active in models of drug-resistant AML. Blood 2013;122:1455–63.
12. Miller ML, Fishkin NE, Li W, Whiteman KR, Kovtun Y, Reid EE, et al. A New class of antibody–drug conjugates with potent DNA alkylating activity. Mol Cancer Ther 2016;15:1870–8.
13. Pillow TH, Schutten M, Yu SF, Ohri R, Sadowsky J, Poon KA, et al. Modulating therapeutic activity and toxicity of pyrrolobenzodiazepine antibody–drug conjugates with self-immolative disulfide linkers. Mol Cancer Ther 2017;16:871–8.
14. Harper J, Lloyd C, Dimasi N, Toader D, Marwood R, Lewis L, et al. Preclinical evaluation of MEDI0641, a pyrrolobenzodiazepine-conjugated antibody–drug conjugate targeting 5T4. Mol Cancer Ther 2017;16: 1576–87.
15. Polakis P. Antibody drug conjugates for cancer therapy. Pharmacol Rev 2016;68:3–19.
16. Godwin CD, Gale RP, Walter RB. Gemtuzumab ozogamicin in acute myeloid leukemia. Leukemia 2017;31:1855–68.
17. Appelbaum FR, Bernstein ID. Gemtuzumab ozogamicin for acute myeloid leukemia. Blood 2017;31:1855–68.
18. Rudin CM, Pietanza MC, Bauer TM, Ready N, Morgensztern D, Glisson BS, et al. Rovalpituzumab tesirine, a DLL3-targeted antibody–drug conjugate, in recurrent small-cell lung cancer: a first-in-human, first-in-class, open-label, phase 1 study. Lancet Oncol 2017;18:42–51.
19. Hartley JA, Spanswick VJ, Brooks N, Clingen PH, McHugh PJ, Hochhauser D, et al. SJG-136 (NSC 694501), a novel rationally designed DNA minor groove interstrand cross-linking agent with potent and broad spectrum antitumor activity: part 1: cellular pharmacology, in vitro and initial in vivo antitumor activity. Cancer Res 2004;64:6693–9.
20. Alley MC, Hollingshead MG, Pacula-Cox CM, Waud WR, Hartley JA, Howard PW, et al. SJG-136 (NSC 694501), a novel rationally designed DNA minor groove interstrand cross-linking agent with potent and broad spectrum antitumor activity: part 2: efficacy evaluations. Cancer Res 2004;64:6700–6.
21. Kovtun YV, Audette CA, Mayo MF, Jones GE, Doherty H, Maloney EK, et al. Antibody–maytansinoid conjugates designed to bypass multidrug resistance. Cancer Res 2010;70:2528–37.
22. Ab O, Whiteman KR, Bartle LM, Sun X, Singh R, Tavares D, et al. IMGN853, a folate receptor-alpha (FRalpha)-targeting antibody–drug conjugate, exhibits potent targeted antitumor activity against FRalpha-expressing tumors. Mol Cancer Ther 2015;14:1605–13.
23. Deckert J, Park PU, Chicklas S, Yi Y, Li M, Lai KC, et al. A novel anti-CD37 antibody–drug conjugate with multiple anti-tumor mechanisms for the treatment of B-cell malignancies. Blood 2013; 122:3500–10.
24. Detre S, Saclani Jotti G, Dowsett M. A "quickscore" method for immunohistochemical semiquantitation: validation for oestrogen receptor in breast carcinomas. J Clin Pathol 1995;48:876–8.
25. Lai KC, Deckert J, Setiady YY, Shah P, Wang L, Chari R, et al. Evaluation of targets for maytansinoid ADC therapy using a novel radiochemical assay. Pharm Res 2015;32:3593–603.
26. Widdison WC, Ponte JF, Coccia JA, Lanieri L, Setiady Y, Dong L, et al. Development of anilino-maytansinoid ADCs that efficiently release cytotoxic metabolites in cancer cells and induce high levels of bystander killing. Bioconjug Chem 2015;26:2261–78.
27. Kovtun YV, Audette CA, Ye Y, Xie H, Ruberti MF, Phinney SJ, et al. Antibody–drug conjugates designed to eradicate tumors with homogeneous and heterogeneous expression of the target antigen. Cancer Res 2006;66:3214–21.
28. Li F, Emmerton KK, Jonas M, Zhang X, Miyamoto JB, Setter JR, et al. Intracellular released payload influences potency and bystander-killing effects of antibody–drug conjugates in preclinical models. Cancer Res 2016;76:2710–9.
29. Ogitani Y, Hagihara K, Oitate M, Naito H, Agatsuma T. Bystander killing effect of DS-8201a, a novel anti-human epidermal growth factor receptor 2 antibody–drug conjugate, in tumors with human epidermal growth factor receptor 2 heterogeneity. Cancer Sci 2016;107:1039–46.
30. Ma Y, Khojasteh SC, Hop CE, Erickson HK, Polson A, Pillow TH, et al. Antibody drug conjugates differentiate uptake and DNA alkylation of pyrrolobenzodiazepines in tumors from organs of xenograft mice. Drug Metab Dispos 2016;44:1958–62.
31. Bardia A, Mayer IA, Diamond JR, Moroose RL, Isakoff SJ, Starodub AN, et al. Efficacy and safety of anti-trop-2 antibody drug conjugate sacituzumab govitecan (IMMU-132) in heavily pretreated patients with metastatic triple-negative breast cancer. J Clin Oncol 2017;35:2141–8.
32. Dotan E, Cohen SJ, Starodub AN, Lieu CH, Messersmith WA, Simpson PS, et al. Phase I/II trial of labetuzumab govitecan (Anti-CEACAM5/SN-38 antibody–drug conjugate) in patients with refractory or relapsing metastatic colorectal cancer. J Clin Oncol 2017:JCO2017739011.
33. Ogitani Y, Aida T, Hagihara K, Yamaguchi J, Ishii C, Harada N, et al. DS-8201a, A novel HER2-Targeting ADC with a novel DNA topoisomerase I inhibitor, demonstrates a promising antitumor efficacy with differentiation from T-DM1. Clin Cancer Res 2016;22:5097–108.
34. de Goeij BE, Lambert JM. New developments for antibody–drug conjugate-based therapeutic approaches. Curr Opin Immunol 2016;40:14–23.
35. Takegawa N, Nonagase Y, Yonesaka K, Sakai K, Maenishi O, Ogitani Y, et al. DS-8201a, a new HER2-targeting antibody–drug conjugate incorporating a novel DNA topoisomerase I inhibitor, overcomes HER2-positive gastric cancer T-DM1 resistance. Int J Cancer 2017;141:1682–9.
36. Wittrup KD, Thurber GM, Schmidt MM, Rhoden JJ. Practical theoretic guidance for the design of tumor-targeting agents. Methods Enzymol 2012;503:255–68.
37. Thurber GM, Schmidt MM, Wittrup KD. Antibody tumor penetration: transport opposed by systemic and antigen-mediated clearance. Adv Drug Deliv Rev 2008;60:1421–34.